Skip to main content

UTHR

Stock
Health Care
Biotechnology

Performance overview

UTHR Price
Price Chart

Forward-looking statistics

Beta
0.55
Risk
32.20%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

Company info

SectorHealth Care
IndustryBiotechnology
Employees1K
Market cap$12.2B

Fundamentals

Enterprise value$9.8B
Revenue$3.0B
Revenue per employee—
Profit margin40.44%
Debt to equity2.94

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$25.09
Dividend per share—
Revenue per share$67.02
Avg trading volume (30 day)$186M
Avg trading volume (10 day)$154M
Put-call ratio—

Macro factor sensitivity

Growth+2.4
Credit+1.8
Liquidity-0.6
Inflation+0.4
Commodities+0.4
Interest Rates-1.1

Valuation

Dividend yield0.00%
PEG Ratio10.56
Price to sales4.44
P/E Ratio10.56
Enterprise Value to Revenue3.29
Price to book1.95

Upcoming events

Next earnings dayApril 30, 2025
Next dividend day—
Ex. dividend day—

News

Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research (July 11, 2025)
United Therapeutics (UTHR) Soars 3.5%: Is Further Upside Left in the Stock?

United Therapeutics (UTHR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Investment Research (June 13, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free